Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the histone deacetylase inhibitors market size evolved in recent years?

In recent times, there has been a significant increase in the market size of histone deacetylase inhibitors. The market is predicted to expand from $1.2 billion in 2024 to $1.3 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.2%. The past growth in this market can be linked to regulatory backing and swift approvals, the increasing rate of cancer occurrences, enhanced funding dedicated to cancer research, the broadening of therapeutic uses, and higher spending on health infrastructure.

What are the predictions for the histone deacetylase inhibitors market size in the coming years?

Over the coming years, the market size of histone deacetylase inhibitors is projected to witness significant enhancement. By 2029, it is anticipated to reach $1.77 billion with a Compound Annual Growth Rate (CAGR) of 7.9%. The predicted growth during the forecast period might come as a result of increased investment in the biotechnology sector, an aging population, favorable regulatory endorsements, expedited drug approval procedures, advanced drug delivery systems, and growth in therapeutic applications. Upcoming trends for the forecast period comprise incorporation of wearable health-tracking gadgets, pioneering developments in nanotechnology and drug delivery techniques, progress in identifying and authenticating biomarkers, artificial intelligence and machine learning breakthroughs, alongside next-generation sequencing.

Get your histone deacetylase inhibitors market report here!

https://www.thebusinessresearchcompany.com/report/histone-deacetylase-inhibitors-global-market-report

What key factors are fueling the growth of the histone deacetylase inhibitors market?

The escalating rates of cancer are poised to boost the histone deacetylase inhibitors market in the near future. The swell in cancer cases is chiefly due to an aging demographic, greater exposure to risk factors such as environmental pollutants, diet, and tobacco, and advancements in diagnostic techniques that allow for more frequent and earlier detection. Cancer is treated with Histone deacetylase inhibitors by modifying the chromatin structure, which activates tumor suppressor genes and suppresses oncogenes, resulting in the arrest of the cell cycle and apoptosis in cancer cells. For example, the World Health Organization, a U.S.-based intergovernmental organization, predicted in February 2024 an approximate 35 million new cancer cases by 2050, an escalation of 77% from the projected 20 million cases in 2022. Consequently, the growing incidence of cancer is steering the advancement of the histone deacetylase inhibitors market.

How is the global histone deacetylase inhibitors market divided into key segments?

The histone deacetylase inhibitors market covered in this report is segmented –

1) By Classification: Class I Histone Deacetylases (HDACs), Class II Histone Deacetylases (HDACs), Class III Histone Deacetylases (HDACs), Other Classifications

2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Oncology, Neurology, Other Applications

5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Suubsegments:

1) By Class I Histone Deacetylases (HDACs): HDAC1 Inhibitors, HDAC2 Inhibitors, HDAC3 Inhibitors, HDAC8 Inhibitors

2) By Class II Histone Deacetylases (HDACs): HDAC4 Inhibitors, HDAC5 Inhibitors, HDAC6 Inhibitors, HDAC7 Inhibitors, HDAC9 Inhibitors, HDAC10 Inhibitors

3) By Class III Histone Deacetylases (HDACs): Sirtuin 1 (SIRT1) Inhibitors, Sirtuin 2 (SIRT2) Inhibitors, Sirtuin 3 (SIRT3) Inhibitors, Sirtuin 4 (SIRT4) Inhibitors, Sirtuin 5 (SIRT5) Inhibitors, Sirtuin 6 (SIRT6) Inhibitors, Sirtuin 7 (SIRT7) Inhibitors

4) By Other Classifications: Dual-acting HDAC Inhibitors, Pan-HDAC Inhibitors, Selective HDAC Inhibitors, Combination Inhibitors (HDAC + Other Mechanisms)

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17170&type=smp

Who are the key firms paving the way for growth in the histone deacetylase inhibitors market?

Major companies operating in the histone deacetylase inhibitors market are Merck & Co. Inc., AstraZeneca plc, Novartis AG, Eisai Co. Ltd., Aurobindo Pharma Limited, Karyopharm Therapeutics Inc., Syndax Pharmaceuticals Inc., MEI Pharma Inc., Italfarmaco S.p.A., Tokyo Chemical Industry Co. Ltd., InvivoGen Corp., Huya Bioscience International LLC, Crystal Genomics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Celgene Corporation, Celleron Therapeutics, Medivir AB, Onxeo SA, Regenacy Pharmaceuticals Inc., Shenzhen Chipscreen Biosciences Co. Ltd., Wellness Pharma International LLC, Forum Pharmaceuticals Inc., Midatech Pharma PLC

What key trends are currently impacting the histone deacetylase inhibitors market’s development?

Dominant players in the histone deacetylase inhibitors market are prioritizing the creation of novel product compositions, such as oral histone deacetylase (HDAC) inhibitors, with the intention of broadening treatment alternatives and enhancing patient convenience and adherence. Oral histone deacetylase (HDAC) inhibitors are orally administered drugs that target HDAC enzymes crucial for gene regulation, potentially beneficial in the treatment of a range of diseases, including cancer and inflammatory disorders. For example, Italfarmaco S.p.A., a pharmaceutical firm based in Italy, earned FDA approval for Duvyzat (givinostat), an oral histone deacetylase (HDAC) inhibitor, for the management of Duchenne muscular dystrophy (DMD) in patients 6 years of age or older, in March 2024. Duvyzat, a histone deacetylase (HDAC) inhibitor, counters the sequence of events leading to muscular damage, possibly delaying the advancement of muscle degeneration linked with DMD. It curtails inflammation and fibrosis while encouraging muscle fiber regrowth by restraining HDAC hyperactivity. The approval was grounded on the critical phase 3 EPIDYS trial, which achieved its primary endpoint, proving a statistically significant reduction in the time required for patients on Duvyzat to finish the four-stair climb assessment compared to those on a placebo.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17170

What regions are contributing significantly to the growth of the histone deacetylase inhibitors market?

North America was the largest region in the histone deacetylase inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Interleukin Inhibitors Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/interleukin-inhibitor-global-market-report

ACE Inhibitors Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Checkpoint Inhibitors Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: